The global menopausal hot flashes market was recorded at US$3.8 bn in 2014. It is progressing at a CAGR of 3.70% within a forecast period from 2015 to 2023, and will reach US$5.3 bn by the end of 2023, according to a research report released by Transparency Market Research. The report, titled “Menopausal Hot Flashes Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023,” encapsulates the key drivers, restraints, and trends regarding the treatments for menopausal hot flashes in the coming years. .
Get Free Sample Research Report:
Hot flashes, also known as hot flushes, can be described as a rapid sensation of heat within the body. It is accompanied by a blushed red face and sweating. They occur during or immediately before menopause and can be repetitive. More than two-thirds of the women in North America are affected by hot flashes during perimenopause. Hot flashes are caused by the dilation of blood vessels close to the skin. Some women also experience chills and a sudden increase in the heart rate. The exact cause of hot flashes is not yet fully understood. The intensity of a hot flash varies from woman to woman.
The report segments the global menopausal hot flashes market in terms of therapy type, pipeline drug, and geography.
On the basis of therapy type, the global menopausal hot flashes market is segmented into hormonal and non-hormonal therapies. The two most common hormones used to treat menopausal hot flashes are progesterone and estrogen, of which the market is led by estrogen. It held the largest share in the market in 2014 in terms of volume of prescription and revenue generated. It is considered to be the most effective way to treat hot flashes and no other treatment has come close to it in terms of effectiveness.
Despite this, non-estrogen treatments are expected to show a decent growth rate. They are almost 70% effective when compared to estrogen treatments and are showing an increase in demand over time.
Geographically speaking, the report puts North America as the dominant region in the global menopausal hot flashes market for 2014, followed closely by Europe. The high growth rate of this market in both regions is owed to the larger percentage of older women in the overall population, since they are also capable of purchasing treatment options for hot flashes. The growth of these two regions in the near future can come from the increasing demand for non-hormonal drugs.
At the same time, the report expects Asia Pacific to show the fastest growth rate in the global menopausal hot flashes market for the given forecast period, owing to its rapidly increasing population density, the increasing number of individuals with a high disposable income, and higher healthcare expenditure and growing knowledge of women’s health issues. Similar growth rates can be seen in the Rest of the World segment. For instance, nearly 32% of the 30 mn women in Brazil are currently aged between 30 and 65 years. This provides a large enough opportunity for the global menopausal hot flashes market to grow in these regions.
In terms of the competitive landscape, the global menopausal hot flashes market is a highly fragmented one. A large portion of the market is taken up by small and mid-sized companies that produce generic treatment options. Nearly 44.50% of the global menopausal hot flashes market was occupied by only a few dominant players in 2014. These key players include Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Novo Nordisk Corporation, Novartis International AG, Merck & Co., Inc., Hisamitsu Pharmaceutical Co., Inc., Bayer AG, and Allergan plc.
Full Research Report on Global Menopausal Hot Flashes Market: